1Xu SY, Pauksen K, Venge P. Serum measurements of human neutrophil lipocalin(HNL) discriminate between acute bacterial and viral infeetions[J].Seand J Clin Lab Invest, 1995,55 (2) : 534-539.
2Xu SY, Petersson CG, Carlson M, et al. The development of an assay for human neutrophil lipocalin (HNL) -to be used as a specific marker of neutrophil activity in vivo and vitro[J]. J Immunol Methods,1994,171(2) :245-252.
5Bjorkqvist M, Kallman J, Fjaertoft G, et al. Human neutrophil lipocalin : normal levels and use as a marker for invasive infection in the newborn[J].Acta Paediatr,2004,934(9):534-539.
6Axelsson L, Bergenfeldt M, Ohlsson K. Studies of the release and turnover of a human neutrophil lipocalin[J].Seand J Clin Lab Invest,1995,55(7):577-588.
7Fjaertoft G,Foucard T, Xu S, et al. Human neutrophil lipocalin(HNL) as a diagnostic tool in children with acute infections: a study of the kinetics[J]. Acta Pediatrica,2005,94(6) :661-666.
4Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med, 2001, 29(7):1303-1310.
5Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guideline. Infect Control Hosp Epidemiol, 1996, 17(6):356-359.
6Snider RH, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med, 1997, 45(9):552-560.
7American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med, 1992, 20(6):864-874.
8Vincent JL, Moreno R, Takala J, et al. The SOFA score to describe organ dysfunction/failure. Intensive Care Med,1996, 22(7):707-710.
9Oberhoffer M, Vogelsang H, Russwurm S, et al. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med, 1999, 37(3):363-368.
10Hausfater P, Garric S, Ayed B, et al. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis,2002, 34(7):895-901.
1Xu SY, Carlson M, Engstrom A, et al. Purification and characterization of a human neutrophil lipocalin (I-INL) from the secondary granules of human neutrophils. Scand J Clin Lab Invest, 1994, 54 (5): 365-376.
2Xu SY, Pauksen K, Venge P. Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infections. Scand J Clin Lab Invest, 1995, 55(2): 125-131.
3Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta, 2000, 1482(I-2): 298-307.
4Xu SY, Petersson CG, Carlson M, et al. The development of an assay for human neutrophil lipocalin (HNL)-to be used as a specific marker of neutrophil activity in vivo and vitro. J Immunol Methods, 1994, 171(2): 245-252.
5杨道理,胡成进.检验与临床诊断免疫性疾病分册.北京:人民军医出版社,2006:104-112.
6Fjaertoft G, Foucard T, Xu S, et al. Human neutrophil lipocalin (HNL) as a diagnostic tool in children with acute infections: a study of the kinetics. Aeta Paediatr, 2005, 94 (6): 661-666.
7Bjorkqvist M, Kallman J, Fjaertoft G, et al. Human neutrophil lipocalin: normal levels and use as a marker for invasive infection in the newborn. Acta Paediatr, 2004, 93 (4): 534-539.
8Schmidt-Ott KM, Mori K, Li JY, et al. Dual action of neutrophil gelatinase-associated lipocalin [J]. J Am Soc Nephrol, 2007, 18 (2): 407-413.
9Vaidya VS, Ferguson MA, Bonventre JV, et al. Biomarkers of a- cute kidney injury [Jl. Annu Rev Pharmacol Toxicol, 2008, 48 (2): 463-493.
10Devarajan P. Emerging urinay biomarkers in the diagnosis of acute kidney injury [J]. Expert Opin Med Diagn, 2008, 2 (4): 387-398.
